https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=20456921&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09 204569212010110320100531
1095-91573512010AugJournal of autoimmunityJ AutoimmunAnti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance.869786-9710.1016/j.jaut.2010.03.003Membrane (m)IgD forms a major part of B-cell receptor complexes. Its wider role in the immune system has been enigmatic. Stimulation of mIgD with an antibody (anti-IgD) can activate B-cells and elicit a broad immune response in vivo. Given the role of B-cells in autoimmune diseases and the profound impact of anti-IgD on B-cells, the potential effects of anti-IgD on autoimmune conditions are intriguing and yet to be explored. Here we report a novel therapeutic effect of anti-IgD in the collagen-induced arthritis (CIA) mouse model. Administration of anti-IgD at the onset of early clinical symptoms as a therapeutic intervention, but not as a prophylactic treatment, significantly ameliorates disease severity and joint pathology. Anti-IgD treatment selectively depletes mature B cells while it spares regulatory B-cell subsets. This results in a significant reduction of autoantibody levels but does not affect antibody responses to a T-cell-dependent antigen. Therapeutic treatment with anti-IgD increases the numbers of regulatory B-cells and regulatory T-cells whilst it augments adaptive Th1/Th2 responses in vivo. In human PBMC samples, anti-IgD also promotes adaptive Th1/Th2 responses and modulates the innate responses toward an anti-inflammatory Th2-biased response. Collectively, anti-IgD treatment may offer a selective approach to B-cell depletion that also promotes immune tolerance and anti-inflammatory tendencies without compromising the general adaptive B-cell and T-cell responses. The multiple mechanisms of action by anti-IgD treatment suggest a wider clinical application for a number of chronic inflammatory and autoimmune conditions.NguyenTue GTGPerinatal Research, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia. tgnguyen@med.usyd.edu.au <tgnguyen@med.usyd.edu.au>LittleChristopher BCBYensonVanessa MVMJacksonChristopher JCJMcCrackenSharon ASAWarningJuliaJStevensVeronicaVGalleryEileen GEGMorrisJonathan MJMengJournal ArticleResearch Support, Non-U.S. Gov't20100424
EnglandJ Autoimmun88121640896-84110Antibodies, Anti-Idiotypic0anti-IgDIMAdaptive Immunitydrug effectsAnimalsAntibodies, Anti-IdiotypicpharmacologyArthritis, Experimentaldrug therapyimmunologypathologyphysiopathologyB-Lymphocytesdrug effectsimmunologymetabolismpathologyDisease ProgressionHumansImmune Tolerancedrug effectsImmunity, Innatedrug effectsImmunotherapyJointsdrug effectspathologyLymphocyte DepletionLymphocyte Subsetsdrug effectsimmunologymetabolismpathologyMaleMiceMice, Inbred DBATh1 Cellsdrug effectsimmunologyTh2 Cellsdrug effectsimmunology
201021920103172010321201051260201051260201011460ppublish2045692110.1016/j.jaut.2010.03.003S0896-8411(10)00035-1